Abstract:
The symptoms can be aspecific: asthenia, pallor, fever, dizziness and respiratory symptoms. Diagnostic methods include blood analysis, bone marrow aspirate for cytochemical, immunological and cytogenetical analysis, and cerebrospinal fliud (CSF) investigations. Treatment includes intensive multidrug chemotherapy and in selected cases allogenic bone marrow transplantation. Nevertheless, outcome of AML remains poor with overall survival of 35-60%. New therapeutics are required to increase the probability of cure in this serious disorder (Verschuur A. C. et. al., 2004).
Differentiation therapy has been successful as a novel treatment for APL. Several compounds including dimethyl sulfoxide, retinoic acid, phorbol ester and 1, 25-dihydroxy vitamin D3 induce AML cells to differentiate toward mature cells. Among them, retinoic acid induces AML cells to differentiate toward granulocytes, whereas 1, 25-dihydroxy vitamin D3 induces AML cells to differentiate toward monocytes (Hyun-Ock Pae a,b et. al., 2001). The following is the overview of advancement in Differentiation therapy against AML specifically AML-M5.
Key words:
AML, Hematopoietic, Symptoms, Daignostic, Therapeutics, Differentiation Therapy.
For full review click on the link below:
https://docs.google.com/open?id=0BzdHWb7McaBDM3VZMEdMS3pSdm1TSEJJbzc5UVNCUQ
Acute myelocytic leukaemia (AML) is a clonal disorder that is the consequence of acquired somatic mutations in hematopoietic progenitor cells that block normal differentiation and cell death and confer a proliferative growth advantage (Wang R. et. al., 2006). AML is basically a group of malignant bone marrow neoplasms of myeloid precursors of white blood cells.
The symptoms can be aspecific: asthenia, pallor, fever, dizziness and respiratory symptoms. Diagnostic methods include blood analysis, bone marrow aspirate for cytochemical, immunological and cytogenetical analysis, and cerebrospinal fliud (CSF) investigations. Treatment includes intensive multidrug chemotherapy and in selected cases allogenic bone marrow transplantation. Nevertheless, outcome of AML remains poor with overall survival of 35-60%. New therapeutics are required to increase the probability of cure in this serious disorder (Verschuur A. C. et. al., 2004).
Differentiation therapy has been successful as a novel treatment for APL. Several compounds including dimethyl sulfoxide, retinoic acid, phorbol ester and 1, 25-dihydroxy vitamin D3 induce AML cells to differentiate toward mature cells. Among them, retinoic acid induces AML cells to differentiate toward granulocytes, whereas 1, 25-dihydroxy vitamin D3 induces AML cells to differentiate toward monocytes (Hyun-Ock Pae a,b et. al., 2001). The following is the overview of advancement in Differentiation therapy against AML specifically AML-M5.
Key words:
AML, Hematopoietic, Symptoms, Daignostic, Therapeutics, Differentiation Therapy.
For full review click on the link below:
https://docs.google.com/open?id=0BzdHWb7McaBDM3VZMEdMS3pSdm1TSEJJbzc5UVNCUQ
No comments:
Post a Comment